OQRO

Feed News

Explore

Insider trades Fund moves Congressional trades Federal contracts Screener

Yours

Watchlist Alerts Saved Ask Claude or ChatGPT

Create a free account Sign in

OQRO

Search/

Loading…

Director received an award of 4,301 CYTK derivative securities | OQRO

Home
Insider trades
Cytokinetics
Director received an award of 4,301 CYTK derivative securities

Insider trades

Insider trade

Director received an award of 4,301 CYTK derivative securities

Traded May 27, 2026 · Filed May 27, 2026

CYTCytokineticsCYTK

4,301
Derivative units

Why it stands out

Compensation award — excluded from discretionary-purchase analysis.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: May 27, 2026
Reporting period: Not applicable
Filed with the SEC: May 27, 2026

DirectorGrant / award

Context

Classification

grant award

Code A — grant or award

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001061983-26-000062
Filed / recorded

Ask Claude or ChatGPT about these filings. Connect OQRO in a minute, then ask things like “which insiders bought this week?”

May 27, 2026, 11:16 PM UTC

Added to OQRO

Oct 6, 2026, 7:14 PM UTC

Parser

form4-xml-v2

Data quality

Verified: identifiers matched exactly

Issuer

CYTOKINETICS INC

Issuer CIK

1061983

Ticker

CYTK

Reporting person

Muna Bhanji

Relationship

Director

Security

Non-Qualified Stock Option (Right to Buy)

Table

Derivative (Table II)

Transaction date

May 27, 2026

Transaction code

Shares / units

4,301

Price per share

$0.00

Acquired / disposed

Acquired (A)

Shares owned after

4,301

Ownership form

Direct

Amendment

Around the same time

Fady Ibraham MalikEVP Research & Development

Filed 4mo ago

3,500Shares · @ $7.80

Traded Jun 23 · filed the same day

Derivative exercise or conversion — not an open-market buy.

More Official record

Fady Ibraham Malik (EVP Research & Development) sold ~$278K of Cytokinetics

Automatic saleFiled 4mo ago

Fady Ibraham MalikEVP Research & Development

Filed 4mo ago

3,500Derivative units

Traded Jun 23 · filed the same day

Derivative exercise or conversion — not an open-market buy.

More Official record